Thursday, March 23, 2023
News on Pathogens and Preparedness
Global Biodefense
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
Global Biodefense
No Result
View All Result
Home Biosecurity

Indo-U.S. Vaccine Action Program Small Research Grants

by Global Biodefense Staff
April 10, 2013

Influenza and Infectious Disease Research ProgramsThe National Institute of Allergy and Infectious Diseases (NIAID) has issued a grant opportunity to fund research activities leading to the development of new and improved vaccines and related products and technologies to combat infectious diseases of importance in India, the U.S., the South Asian region and globally. 

Applications are encouraged from organizations that propose to conduct vaccine-related research through U.S.-Indo collaborations on the following: dengue, influenza (including avian influenza), malaria, enteric diseases, HIV/AIDS, and tuberculosis.  Basic, translational, clinical, or epidemiological vaccine research may be proposed.

Special initiatives have been undertaken over the years in an effort to advance cooperation with India more rapidly and effectively in some areas, and cooperation in the health sciences has been particularly prominent. One of the most important and successful of these has been the Indo-U.S. Vaccine Action Program (VAP), a jointly administered and funded bilateral vaccine research program, which has supported approximately 60 collaborative research projects since its inception in 1987.

“The continued work of the VAP program is an important recognition that vaccines are among the most cost-effective of health technologies and their widespread use in both countries is key to controlling the burden of vaccine-preventable diseases,” states the announcement. “With the emergence of new infectious diseases and increasing attention to health programs which promote child survival, there is renewed interest in attacking this important category of diseases across the full spectrum of scientific, medical and public health disciplines.”  

While applicants should provide evidence of ongoing or proposed scientific collaborations specific to the research proposed in the grant application, this initiative will not require joint application, review and funding of applications by the U.S. and India as was required in previous VAP-supported research projects. Standard NIH/NIAID application and review procedures will be followed. 

Basic, translational, clinical, or epidemiological vaccine research may be proposed under this program.  Further details are available at the National Institutes of Health grants website under: PA-13-179.

Tags: Avian InfluenzaDengueMalariaTuberculosisVaccines

Related Posts

Partner Therapeutics’ Novel Approach to Stratify Sepsis Patients Gains Backing From BARDA
Funding News

Biopreparedness Research Virtual Environment (BRaVE) Initiative Backed by $105M DOE Funding

January 25, 2023
DARPA Selects Teams to Develop Vaccine Durability Prediction Model
Medical Countermeasures

DARPA Selects Teams to Develop Vaccine Durability Prediction Model

January 13, 2023
small glass vials on an assembly line await filling of vaccine solution
Industry News

Sabin Vaccine Institute to Advance Ebola Sudan and Marburg Vaccines with New BARDA Funding

January 12, 2023
How Are Bivalent COVID Vaccines Stacking Up Against Omicron?
Infectious Diseases

How Are Bivalent COVID Vaccines Stacking Up Against Omicron?

January 12, 2023
Load More

Latest News

Biodefense Headlines – 12 March 2023

Biodefense Headlines – 12 March 2023

March 12, 2023
Partner Therapeutics’ Novel Approach to Stratify Sepsis Patients Gains Backing From BARDA

Biopreparedness Research Virtual Environment (BRaVE) Initiative Backed by $105M DOE Funding

January 25, 2023
Influenza Proteins Tilt and Wave in ‘Breath-like’ Motions

Influenza Proteins Tilt and Wave in ‘Breath-like’ Motions

January 25, 2023
Biodefense Headlines – 24 January 2023

Biodefense Headlines – 24 January 2023

January 24, 2023

Subscribe

  • About
  • Contact
  • Privacy
  • Subscribe

© 2022 Stemar Media Group LLC

No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe

© 2022 Stemar Media Group LLC